Last reviewed · How we verify
AZD6094 — Competitive Intelligence Brief
phase 2
CD73 inhibitor
CD73
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
AZD6094 (AZD6094) — Samsung Medical Center. AZD6094 is a small molecule inhibitor of the CD73 enzyme.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AZD6094 TARGET | AZD6094 | Samsung Medical Center | phase 2 | CD73 inhibitor | CD73 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (CD73 inhibitor class)
- AstraZeneca · 1 drug in this class
- BeiGene · 1 drug in this class
- Galderma R&D · 1 drug in this class
- Samsung Medical Center · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AZD6094 CI watch — RSS
- AZD6094 CI watch — Atom
- AZD6094 CI watch — JSON
- AZD6094 alone — RSS
- Whole CD73 inhibitor class — RSS
Cite this brief
Drug Landscape (2026). AZD6094 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd6094. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing